PRCT vs. NVO
PRCT (PROCEPT BioRobotics Corporation) and NVO (Novo Nordisk A/S) are both stocks. Both are in the Healthcare sector — PRCT in Medical Devices, NVO in Drug Manufacturers - General. Over the past 3 years, PRCT returned -18.12%/yr vs -14.32%/yr for NVO. Their 0.19 correlation means their historical movements had little consistent relationship.
Performance
PRCT vs. NVO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PRCT achieves a -40.81% return, which is significantly lower than NVO's -4.23% return.
PRCT
- 1D
- 3.44%
- 1M
- -11.46%
- 6M
- -35.70%
- YTD
- -40.81%
- 1Y
- -62.73%
- 3Y*
- -18.12%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -12.15%
NVO
- 1D
- -8.78%
- 1M
- -6.64%
- 6M
- -18.01%
- YTD
- -4.23%
- 1Y
- 2.25%
- 3Y*
- -14.32%
- 5Y*
- 2.48%
- 10Y*
- 7.55%
- ALL TIME*
- 14.37%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $504.41M | $480.49M | $577.88M | |
| $23.55M | $28.81M | $36.39M |
PRCT vs. NVO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
PRCT PROCEPT BioRobotics Corporation | -40.81% | -60.93% | 92.13% | 0.89% | 66.09% | -28.54% |
NVO Novo Nordisk A/S | -4.23% | -39.22% | -15.93% | 54.84% | 22.66% | 11.97% |
Correlation
The correlation between PRCT and NVO is 0.20, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.20 |
Correlation (3Y) Balances recent behavior with more history. | 0.16 |
Correlation (All Time) Calculated using the full available price history since Sep 15, 2021 | 0.19 |
Fundamentals
PRCT:
$1.06B
NVO:
$209.19B
PRCT:
-$2.76
NVO:
DKK 27.42
PRCT:
2.15
NVO:
4.15
PRCT:
$322.02M
NVO:
DKK 327.80B
PRCT:
$206.01M
NVO:
DKK 268.30B
PRCT:
-$90.33M
NVO:
DKK 181.54B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PRCT vs. NVO — Risk / Return Rank
PRCT
NVO
PRCT vs. NVO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for PROCEPT BioRobotics Corporation (PRCT) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PRCT | NVO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.08 | ||
| Sortino ratioReturn per unit of downside risk | -2.10 | ||
| Omega ratioGain probability vs. loss probability | 0.82 | 1.06 | -0.25 |
| Calmar ratioReturn relative to maximum drawdown | -0.93 | 0.11 | -1.04 |
| Martin ratioReturn relative to average drawdown | -1.46 | 0.20 | -1.66 |
Loading charts...
Drawdowns
PRCT vs. NVO - Drawdown Comparison
The maximum PRCT drawdown since its inception was -83.22%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for PRCT and NVO.
Loading charts...
Drawdown Indicators
| PRCT | NVO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.22% | -74.70% | -8.52% |
Max Drawdown (1Y)Largest decline over 1 year | -66.59% | -43.67% | -22.92% |
Max Drawdown (3Y)Largest decline over 3 years | -83.22% | -74.70% | -8.52% |
Max Drawdown (5Y)Largest decline over 5 years | — | -74.70% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -74.70% | — |
Current DrawdownCurrent decline from peak | -81.28% | -65.79% | -15.49% |
Average DrawdownAverage peak-to-trough decline | -33.17% | -17.93% | -15.24% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 42.20% | 23.97% | +18.23% |
Volatility
PRCT vs. NVO - Volatility Comparison
PROCEPT BioRobotics Corporation (PRCT) has a higher volatility of 19.68% compared to Novo Nordisk A/S (NVO) at 12.28%. This indicates that PRCT's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PRCT | NVO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 19.68% | 12.28% | +7.40% |
Volatility (6M)Calculated over the trailing 6-month period | 49.70% | 36.87% | +12.83% |
Volatility (1Y)Calculated over the trailing 1-year period | 63.51% | 46.77% | +16.74% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 65.49% | 38.76% | +26.73% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 65.49% | 32.76% | +32.73% |
Dividends
PRCT vs. NVO - Dividend Comparison
PRCT has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 3.83%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 3.83% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
PRCT PROCEPT BioRobotics Corporation | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
PRCT vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between PROCEPT BioRobotics Corporation and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
PRCT vs. NVO - Profitability Comparison
PRCT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, PROCEPT BioRobotics Corporation reported a gross profit of 53.95M and revenue of 83.13M. Therefore, the gross margin over that period was 64.9%.
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.
PRCT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, PROCEPT BioRobotics Corporation reported an operating income of -32.61M and revenue of 83.13M, resulting in an operating margin of -39.2%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.
PRCT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, PROCEPT BioRobotics Corporation reported a net income of -31.64M and revenue of 83.13M, resulting in a net margin of -38.1%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.
Frequently Asked Questions
PRCT and NVO have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
PRCT has higher volatility (19.68%) compared to NVO (12.28%). In terms of maximum drawdown, PRCT dropped -83.22% vs NVO's -74.70%.
NVO currently has the higher Sharpe Ratio (0.10 vs -0.98), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PRCT and NVO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer